Inhibiting the Growth of Pancreatic Adenocarcinoma In Vitro and In Vivo through Targeted Treatment with Designer Gold Nanotherapeutics

• Rachel A. Kudgus,

  Affiliation Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯
• Annamaria Szabolcs,

  Affiliation Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯
• Jameel Ahmad Khan,

  Affiliation Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯
• Chad A. Walden,

  Affiliation Department of Physiology and Biomedical Engineering, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯
• Joel M. Reid,

  Affiliation Department of Physiology and Biomedical Engineering, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯
• J. David Robertson,

  Affiliation Department of Chemistry and University of Missouri Research Reactor, University of Missouri, Columbia, Missouri, United States of America

  ⨯
• Resham Bhattacharya,

  Affiliation Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯
• Priyabrata Mukherjee

  * E-mail: Mukherjee.priyabrata@mayo.edu

  Affiliations Department of Biochemistry and Molecular Biology, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America, Department of Physiology and Biomedical Engineering, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America, Mayo Clinic Cancer Center, College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America

  ⨯